Harmony Biosciences (HRMY) Stock Forecast, Price Target & Predictions
HRMY Stock Forecast
Harmony Biosciences stock forecast is as follows: an average price target of $50.67 (represents a 30.22% upside from HRMY’s last price of $38.91) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
HRMY Price Target
The average price target for Harmony Biosciences (HRMY) is $50.67 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $61.00 to $37.00. This represents a potential 30.22% upside from HRMY's last price of $38.91.
HRMY Analyst Ratings
According to 7 Wall Street analysts, Harmony Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for HRMY stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 1 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Harmony Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 10, 2024 | Ashwani Verma | UBS | $56.00 | $36.89 | 51.80% | 43.92% |
| Aug 08, 2024 | Graig Suvannavejh | Mizuho Securities | $42.00 | $33.55 | 25.19% | 7.94% |
| Jun 24, 2024 | Francois Brisebois | Oppenheimer | $56.00 | $30.39 | 84.27% | 43.92% |
| May 01, 2024 | Ami Fadia | Needham | $52.00 | $30.37 | 71.22% | 33.64% |
| Apr 30, 2024 | Danielle Brill | Raymond James | $37.00 | $30.91 | 19.70% | -4.91% |
| Oct 14, 2022 | Chris Howerton | Jefferies | $61.00 | $47.63 | 28.07% | 56.77% |
The latest Harmony Biosciences stock forecast, released on Sep 10, 2024 by Ashwani Verma from UBS, set a price target of $56.00, which represents a 51.80% increase from the stock price at the time of the forecast ($36.89), and a 43.92% increase from HRMY last price ($38.91).
Harmony Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 3 | 5 |
| Avg Price Target | $56.00 | $51.33 | $48.60 |
| Last Closing Price | $38.91 | $38.91 | $38.91 |
| Upside/Downside | 43.92% | 31.92% | 24.90% |
In the current month, the average price target of Harmony Biosciences stock is $56.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 43.92% increase as opposed to Harmony Biosciences's last price of $38.91. This month's average price target is up 9.10% compared to last quarter, and up 15.23% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 12, 2024 | Needham | Buy | Buy | Hold |
| Sep 10, 2024 | UBS | Buy | Buy | Hold |
| Sep 10, 2024 | Needham | Underperform | Underperform | Hold |
| Sep 09, 2024 | UBS | - | Buy | Initialise |
| Aug 06, 2024 | Needham | Buy | Buy | Hold |
| Jun 24, 2024 | Citigroup | Buy | Buy | Hold |
| Jun 24, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jun 21, 2024 | Needham | Buy | Buy | Hold |
| Jun 21, 2024 | Citigroup | Underperform | Underperform | Hold |
| Jun 20, 2024 | Citigroup | - | Buy | Initialise |
Harmony Biosciences's last stock rating was published by Needham on Sep 12, 2024. The company gave HRMY a "Buy" rating, the same as its previous rate.
Harmony Biosciences Financial Forecast
Harmony Biosciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $160.27M | $134.22M | $119.13M | $128.31M | $117.21M | - | $85.31M | $91.21M | $80.73M | $73.82M | $59.67M | $56.29M | $45.61M |
| Avg Forecast | $290.03M | $261.02M | $242.63M | $217.08M | $237.19M | $223.34M | $201.87M | $181.85M | $198.12M | $184.80M | $172.53M | $154.10M | $169.02M | $147.83M | $142.01M | $120.14M | $127.66M | $113.59M | $100.73M | $88.55M | $89.53M | $79.90M | $68.83M | $57.20M | $51.89M | $40.00M |
| High Forecast | $296.13M | $266.50M | $247.73M | $221.64M | $242.17M | $228.03M | $206.12M | $185.67M | $202.29M | $185.86M | $176.15M | $157.34M | $169.67M | $156.89M | $145.00M | $122.66M | $130.35M | $115.97M | $100.73M | $90.85M | $91.85M | $81.98M | $70.62M | $58.69M | $53.24M | $41.04M |
| Low Forecast | $285.92M | $257.31M | $239.19M | $214.00M | $233.82M | $220.17M | $199.01M | $179.27M | $195.31M | $183.73M | $170.08M | $151.91M | $168.37M | $139.32M | $140.00M | $118.43M | $125.85M | $111.98M | $100.73M | $86.49M | $87.44M | $78.04M | $67.23M | $55.87M | $50.68M | $39.07M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 2 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 4 | 6 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.08% | 0.95% | 0.99% | 1.01% | 1.03% | - | 0.96% | 1.02% | 1.01% | 1.07% | 1.04% | 1.08% | 1.14% |
Harmony Biosciences's average Quarter revenue forecast for Dec 23 based on 2 analysts is $169.02M, with a low forecast of $168.37M, and a high forecast of $169.67M. HRMY's average Quarter revenue forecast represents a 5.46% increase compared to the company's last Quarter revenue of $160.27M (Sep 23).
Harmony Biosciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 2 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 4 | 6 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $64.51M | $46.90M | $46.49M | $47.69M | $18.02M | - | $32.75M | $33.42M | $-5.85M | $20.82M | $12.06M | $12.14M | $10.82M |
| Avg Forecast | $2.67M | $2.40M | $2.23M | $2.00M | $2.18M | $2.05M | $1.86M | $1.67M | $1.82M | $1.70M | $1.59M | $40.29M | $1.55M | $1.36M | $1.31M | $36.63M | $1.17M | $-6.28M | $926.09K | $28.96M | $31.57M | $-5.71M | $17.53M | $525.89K | $477.04K | $8.66M |
| High Forecast | $2.72M | $2.45M | $2.28M | $2.04M | $2.23M | $2.10M | $1.89M | $1.71M | $1.86M | $1.71M | $1.62M | $48.35M | $1.56M | $1.44M | $1.33M | $43.96M | $1.20M | $-5.03M | $926.09K | $34.75M | $37.88M | $-4.57M | $21.04M | $539.55K | $489.44K | $10.39M |
| Low Forecast | $2.63M | $2.37M | $2.20M | $1.97M | $2.15M | $2.02M | $1.83M | $1.65M | $1.80M | $1.69M | $1.56M | $32.23M | $1.55M | $1.28M | $1.29M | $29.30M | $1.16M | $-7.54M | $926.09K | $23.16M | $25.25M | $-6.85M | $14.02M | $513.62K | $465.92K | $6.93M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 47.46% | 35.92% | 1.27% | 40.63% | -2.87% | - | 1.13% | 1.06% | 1.02% | 1.19% | 22.94% | 25.45% | 1.25% |
2 analysts predict HRMY's average Quarter EBITDA for Dec 23 to be $1.55M, with a high of $1.56M and a low of $1.55M. This is -97.59% lower than Harmony Biosciences's previous annual EBITDA (Sep 23) of $64.51M.
Harmony Biosciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 2 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 4 | 6 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $38.46M | $34.30M | $29.48M | $48.51M | $87.94M | - | $21.48M | $22.71M | $-9.62M | $14.12M | $7.39M | $-208.00K | $1.91M |
| Avg Forecast | $73.27M | $64.47M | $59.11M | $50.16M | $54.73M | $52.31M | $45.50M | $38.72M | $39.54M | $38.13M | $-95.92K | $26.43M | $41.55M | $38.30M | $35.03M | $24.03M | $33.62M | $-10.33M | $25.92M | $18.99M | $21.45M | $-9.39M | $11.89M | $97.50M | $4.51M | $1.53M |
| High Forecast | $75.27M | $66.23M | $60.72M | $51.53M | $56.23M | $53.74M | $46.74M | $39.78M | $40.62M | $47.67M | $-94.15K | $31.72M | $44.35M | $45.96M | $35.99M | $28.83M | $34.54M | $-8.27M | $25.92M | $22.79M | $25.74M | $-7.51M | $14.27M | $116.99M | $4.66M | $1.83M |
| Low Forecast | $71.92M | $63.28M | $58.02M | $49.24M | $53.72M | $51.35M | $44.66M | $38.01M | $38.81M | $28.60M | $-98.54K | $21.14M | $39.86M | $33.58M | $34.38M | $19.22M | $33.00M | $-12.40M | $25.92M | $15.20M | $17.16M | $-11.27M | $9.51M | $78.00M | $4.38M | $1.22M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 0.98% | 1.23% | 1.44% | -8.51% | - | 1.13% | 1.06% | 1.02% | 1.19% | 0.08% | -0.05% | 1.25% |
Harmony Biosciences's average Quarter net income forecast for Dec 23 is $41.55M, with a range of $39.86M to $44.35M. HRMY's average Quarter net income forecast represents a 8.02% increase compared to the company's last Quarter net income of $38.46M (Sep 23).
Harmony Biosciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 2 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 4 | 6 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $45.96M | $47.34M | $44.63M | $43.72M | $41.80M | - | $35.46M | $37.31M | $33.34M | $31.32M | $30.05M | $30.99M | $23.11M |
| Avg Forecast | $881.72M | $793.51M | $737.61M | $659.93M | $721.06M | $678.96M | $613.71M | $552.83M | $602.31M | $561.81M | $524.49M | $43.63M | $513.84M | $449.40M | $431.72M | $39.66M | $388.10M | $35.81M | $306.22M | $31.35M | $35.24M | $32.55M | $26.38M | $173.89M | $157.74M | $18.49M |
| High Forecast | $900.25M | $810.19M | $753.11M | $673.80M | $736.21M | $693.23M | $626.60M | $564.45M | $614.97M | $565.03M | $535.51M | $52.35M | $515.82M | $476.96M | $440.80M | $47.59M | $396.26M | $42.97M | $306.22M | $37.62M | $42.29M | $39.06M | $31.65M | $178.41M | $161.84M | $22.18M |
| Low Forecast | $869.20M | $782.25M | $727.14M | $650.57M | $710.83M | $669.33M | $605.00M | $544.99M | $593.76M | $558.56M | $517.04M | $34.90M | $511.86M | $423.53M | $425.60M | $31.73M | $382.59M | $28.64M | $306.22M | $25.08M | $28.19M | $26.04M | $21.10M | $169.84M | $154.06M | $14.79M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.10% | 0.11% | 1.13% | 0.11% | 1.17% | - | 1.13% | 1.06% | 1.02% | 1.19% | 0.17% | 0.20% | 1.25% |
Harmony Biosciences's average Quarter SG&A projection for Dec 23 is $513.84M, based on 2 Wall Street analysts, with a range of $511.86M to $515.82M. The forecast indicates a 1017.92% rise compared to HRMY last annual SG&A of $45.96M (Sep 23).
Harmony Biosciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 2 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 4 | 6 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.64 | $0.57 | $0.49 | $0.82 | $1.48 | - | $0.36 | $0.39 | $-0.17 | $0.25 | $0.13 | $-0.00 | $0.06 |
| Avg Forecast | $1.27 | $1.12 | $1.03 | $0.87 | $0.95 | $0.91 | $0.79 | $0.67 | $0.69 | $0.66 | $-0.00 | $0.60 | $0.72 | $0.67 | $0.61 | $0.47 | $0.58 | $0.10 | $0.45 | $0.29 | $0.36 | $0.28 | $0.18 | $-0.03 | $0.08 | $-0.05 |
| High Forecast | $1.31 | $1.15 | $1.06 | $0.90 | $0.98 | $0.93 | $0.81 | $0.69 | $0.71 | $0.83 | $-0.00 | $0.62 | $0.77 | $0.80 | $0.63 | $0.48 | $0.60 | $0.11 | $0.45 | $0.30 | $0.37 | $0.29 | $0.18 | $-0.03 | $0.08 | $-0.05 |
| Low Forecast | $1.25 | $1.10 | $1.01 | $0.86 | $0.93 | $0.89 | $0.78 | $0.66 | $0.67 | $0.50 | $-0.00 | $0.59 | $0.69 | $0.58 | $0.60 | $0.46 | $0.57 | $0.10 | $0.45 | $0.28 | $0.35 | $0.27 | $0.17 | $-0.03 | $0.07 | $-0.05 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.96% | 0.94% | 1.04% | 1.40% | 14.27% | - | 1.23% | 1.09% | -0.61% | 1.42% | -4.87% | -0.05% | -1.35% |
According to 2 Wall Street analysts, Harmony Biosciences's projected average Quarter EPS for Dec 23 is $0.72, with a low estimate of $0.69 and a high estimate of $0.77. This represents a 12.81% increase compared to HRMY previous annual EPS of $0.64 (Sep 23).
Harmony Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.29 | $33.86 | 1378.60% | Buy |
| KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
| GOSS | Gossamer Bio | $0.92 | $3.75 | 307.61% | Buy |
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| FENC | Fennec Pharmaceuticals | $5.47 | $15.75 | 187.93% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| REPL | Replimune Group | $11.13 | $24.20 | 117.43% | Buy |
| GPCR | Structure Therapeutics | $40.84 | $86.00 | 110.58% | Buy |
| SNDX | Syndax Pharmaceuticals | $19.12 | $36.00 | 88.28% | Buy |
| KROS | Keros Therapeutics | $56.98 | $105.00 | 84.28% | Buy |
| LYRA | Lyra Therapeutics | $0.28 | $0.50 | 78.57% | Hold |
| VRDN | Viridian Therapeutics | $22.06 | $37.83 | 71.49% | Buy |
| TVTX | Travere Therapeutics | $13.48 | $21.60 | 60.24% | Buy |
| HRMY | Harmony Biosciences | $38.91 | $50.67 | 30.22% | Buy |
| IDYA | IDEAYA Biosciences | $37.46 | $46.13 | 23.14% | Buy |
| NUVL | Nuvalent | $87.45 | $107.33 | 22.73% | Buy |
| JANX | Janux Therapeutics | $50.01 | $59.25 | 18.48% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| VRNA | Verona Pharma | $29.78 | $33.00 | 10.81% | Buy |
| PTGX | Protagonist Therapeutics | $47.02 | $50.00 | 6.34% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
HRMY Forecast FAQ
Is Harmony Biosciences a good buy?
Yes, according to 7 Wall Street analysts, Harmony Biosciences (HRMY) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 85.71% of HRMY's total ratings.
What is HRMY's price target?
Harmony Biosciences (HRMY) average price target is $50.67 with a range of $37 to $61, implying a 30.22% from its last price of $38.91. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Harmony Biosciences stock go up soon?
According to Wall Street analysts' prediction for HRMY stock, the company can go up by 30.22% (from the last price of $38.91 to the average price target of $50.67), up by 56.77% based on the highest stock price target, and down by -4.91% based on the lowest stock price target.
Can Harmony Biosciences stock reach $60?
HRMY's highest twelve months analyst stock price target of $61 supports the claim that Harmony Biosciences can reach $60 in the near future.
What is Harmony Biosciences's current price target trend?
1 Wall Street analyst forecast a $56 price target for Harmony Biosciences (HRMY) this month, up 43.92% from its last price of $38.91. Compared to the last 3 and 12 months, the average price target increased by 31.92% and increased by 24.90%, respectively.
What are Harmony Biosciences's analysts' financial forecasts?
Harmony Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $844.25M (high $861.99M, low $832.27M), average EBITDA is $7.76M (high $7.93M, low $7.65M), average net income is $191.27M (high $196.49M, low $187.74M), average SG&A $2.57B (high $2.62B, low $2.53B), and average EPS is $3.32 (high $3.41, low $3.26). HRMY's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.01B (high $1.03B, low $996.42M), average EBITDA is $9.29M (high $9.49M, low $9.16M), average net income is $247.01M (high $253.76M, low $242.46M), average SG&A $3.07B (high $3.14B, low $3.03B), and average EPS is $4.29 (high $4.41, low $4.21).
Did the HRMY's actual financial results beat the analysts' financial forecasts?
Based on Harmony Biosciences's last annual report (Dec 2022), the company's revenue was $437.86M, beating the average analysts forecast of $430.53M by 1.70%. Apple's EBITDA was $120.36M, beating the average prediction of $24.77M by 385.84%. The company's net income was $181.47M, beating the average estimation of $68.2M by 166.08%. Apple's SG&A was $163.3M, missing the average forecast of $761.48M by -78.55%. Lastly, the company's EPS was $3.14, beating the average prediction of $1.43 by 119.44%. In terms of the last quarterly report (Sep 2023), Harmony Biosciences's revenue was $160.27M, beating the average analysts' forecast of $147.83M by 8.42%. The company's EBITDA was $64.51M, beating the average prediction of $1.36M by 4646.49%. Harmony Biosciences's net income was $38.46M, beating the average estimation of $38.3M by 0.43%. The company's SG&A was $45.96M, missing the average forecast of $449.4M by -89.77%. Lastly, the company's EPS was $0.64, missing the average prediction of $0.666 by -3.84%